Literature DB >> 27000625

Intermediate filament aggregates cause mitochondrial dysmotility and increase energy demands in giant axonal neuropathy.

Eitan Israeli1, Dilyan I Dryanovski1, Paul T Schumacker2, Navdeep S Chandel3, Jeffrey D Singer4, Jean P Julien5, Robert D Goldman6, Puneet Opal7.   

Abstract

Intermediate filaments (IFs) are cytoskeletal polymers that extend from the nucleus to the cell membrane, giving cells their shape and form. Abnormal accumulation of IFs is involved in the pathogenesis of number neurodegenerative diseases, but none as clearly as giant axonal neuropathy (GAN), a ravaging disease caused by mutations in GAN, encoding gigaxonin. Patients display early and severe degeneration of the peripheral nervous system along with IF accumulation, but it has been difficult to link GAN mutations to any particular dysfunction, in part because GAN null mice have a very mild phenotype. We therefore established a robust dorsal root ganglion neuronal model that mirrors key cellular events underlying GAN. We demonstrate that gigaxonin is crucial for ubiquitin-proteasomal degradation of neuronal IF. Moreover, IF accumulation impairs mitochondrial motility and is associated with metabolic and oxidative stress. These results have implications for other neurological disorders whose pathology includes IF accumulation.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27000625      PMCID: PMC5081048          DOI: 10.1093/hmg/ddw081

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  66 in total

1.  Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin.

Authors:  Bethany L Johnson-Kerner; Faizzan S Ahmad; Alejandro Garcia Diaz; John Palmer Greene; Steven J Gray; Richard Jude Samulski; Wendy K Chung; Rudy Van Coster; Paul Maertens; Scott A Noggle; Christopher E Henderson; Hynek Wichterle
Journal:  Hum Mol Genet       Date:  2014-11-04       Impact factor: 6.150

2.  Imaging dynamic redox changes in mammalian cells with green fluorescent protein indicators.

Authors:  Colette T Dooley; Timothy M Dore; George T Hanson; W Coyt Jackson; S James Remington; Roger Y Tsien
Journal:  J Biol Chem       Date:  2004-02-25       Impact factor: 5.157

3.  Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells.

Authors:  Mingjie Li; Nada Husic; Ying Lin; Heather Christensen; Ibrahim Malik; Sally McIver; Christine M LaPash Daniels; David A Harris; Paul T Kotzbauer; Mark P Goldberg; B Joy Snider
Journal:  J Neurosci Methods       Date:  2010-03-27       Impact factor: 2.390

4.  Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect.

Authors:  Freddy Jeanneteau; Michael J Garabedian; Moses V Chao
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-17       Impact factor: 11.205

Review 5.  Introducing intermediate filaments: from discovery to disease.

Authors:  John E Eriksson; Thomas Dechat; Boris Grin; Brian Helfand; Melissa Mendez; Hanna-Mari Pallari; Robert D Goldman
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

6.  Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein.

Authors:  T Kamitani; K Kito; H P Nguyen; E T Yeh
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Giant axonal neuropathy: an inborn error of organization of intermediate filaments.

Authors:  S D Pena
Journal:  Muscle Nerve       Date:  1982-02       Impact factor: 3.217

9.  Alterations in neural intermediate filament organization: functional implications and the induction of pathological changes related to motor neuron disease.

Authors:  K Straube-West; P A Loomis; P Opal; R D Goldman
Journal:  J Cell Sci       Date:  1996-09       Impact factor: 5.285

10.  Drp1 levels constitutively regulate mitochondrial dynamics and cell survival in cortical neurons.

Authors:  Takuma Uo; Jenny Dworzak; Chizuru Kinoshita; Denise M Inman; Yoshito Kinoshita; Philip J Horner; Richard S Morrison
Journal:  Exp Neurol       Date:  2009-05-13       Impact factor: 5.330

View more
  15 in total

1.  Mutant ataxin1 disrupts cerebellar development in spinocerebellar ataxia type 1.

Authors:  Chandrakanth Reddy Edamakanti; Jeehaeh Do; Alessandro Didonna; Marco Martina; Puneet Opal
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

2.  Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1.

Authors:  Yuan-Shih Hu; Jeehaeh Do; Chandrakanth Reddy Edamakanti; Ameet R Kini; Marco Martina; Samuel I Stupp; Puneet Opal
Journal:  Brain       Date:  2019-02-01       Impact factor: 13.501

3.  Sonic Hedgehog repression underlies gigaxonin mutation-induced motor deficits in giant axonal neuropathy.

Authors:  Yoan Arribat; Karolina S Mysiak; Léa Lescouzères; Alexia Boizot; Maxime Ruiz; Mireille Rossel; Pascale Bomont
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

4.  Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment

Authors:  Po-Han Chen; Jimin Hu; Jianli Wu; Duc T Huynh; Timothy J Smith; Samuel Pan; Brittany J Bisnett; Alexander B Smith; Annie Lu; Brett M Condon; Jen-Tsan Chi; Michael Boyce
Journal:  JCI Insight       Date:  2019-11-26

Review 5.  Revisiting the role of mitochondria in spinal muscular atrophy.

Authors:  Rachel James; Helena Chaytow; Leire M Ledahawsky; Thomas H Gillingwater
Journal:  Cell Mol Life Sci       Date:  2021-04-05       Impact factor: 9.261

Review 6.  Neurofilaments: neurobiological foundations for biomarker applications.

Authors:  Arie R Gafson; Nicolas R Barthélemy; Pascale Bomont; Roxana O Carare; Heather D Durham; Jean-Pierre Julien; Jens Kuhle; David Leppert; Ralph A Nixon; Roy O Weller; Henrik Zetterberg; Paul M Matthews
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

7.  The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP.

Authors:  Ni-Hsuan Lin; Yu-Shan Huang; Puneet Opal; Robert D Goldman; Albee Messing; Ming-Der Perng
Journal:  Mol Biol Cell       Date:  2016-10-26       Impact factor: 4.138

8.  Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy.

Authors:  Markus T Sainio; Emil Ylikallio; Laura Mäenpää; Jenni Lahtela; Pirkko Mattila; Mari Auranen; Johanna Palmio; Henna Tyynismaa
Journal:  Neurol Genet       Date:  2018-06-05

Review 9.  The Axon-Myelin Unit in Development and Degenerative Disease.

Authors:  Ruth M Stassart; Wiebke Möbius; Klaus-Armin Nave; Julia M Edgar
Journal:  Front Neurosci       Date:  2018-07-11       Impact factor: 4.677

10.  Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy.

Authors:  Rachel M Bailey; Diane Armao; Sahana Nagabhushan Kalburgi; Steven J Gray
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-15       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.